Clinical Trial

A Phase Ia/Ib Clinical Study of GH56 Capsules in Subjects With MTAP-Deleted Advanced Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a multicenter, single-arm, open-label, dose-escalation, dose-expansion study to evaluate the safety, tolerability, PK/PD, and preliminary anti-tumor activity of GH56 Capsule in subjects with advanced solid tumors who have failed or are intolerant in standard treatment, or have no standard therapy. The clinical trial will be carried out in two parts: phase Ia study (dose escalation study) and phase Ib (dose expansion study).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-01-22.
Status change: Not Yet Recruiting → Recruiting 2025-03-25
Trial Details
NCT Number NCT06796699
Lead Sponsor Suzhou Genhouse Bio Co., Ltd.
Conditions Advanced Solid Tumors With MTAP Gene Deletion
Enrollment 90 participants
Start Date 2025-03-07
Primary Completion 2027-12-31 (estimated)
Study Completion 2028-02-29 (estimated)
Updated on ClinicalTrials.gov 2025-03-28